Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approva…

Chronic Graft-versus-host Disease (cGVHD)

~Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT06660355

Phase 2

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Partici…

Chronic Graft-Versus-Host Disease (cGVHD)

~Estimated

~$10 – $8,750

Deciphera Pharmaceuticals, LLCNCT06619561